OraSure Technologies, Inc. (NASDAQ:OSUR) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09, Briefing.com reports. The firm had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business’s revenue was up 31.0% compared to the same quarter last year. During the same period last year, the firm posted $0.11 earnings per share. OraSure Technologies updated its Q4 guidance to $0.08-$0.09 EPS.

COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (OSUR) Posts Quarterly Earnings Results” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/02/orasure-technologies-inc-osur-posts-quarterly-earnings-results.html.

In related news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $21.26, for a total value of $1,550,194.16. Following the completion of the sale, the executive vice president now directly owns 218,326 shares in the company, valued at $4,641,610.76. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 717,601 shares of company stock valued at $14,977,398. 6.40% of the stock is owned by corporate insiders.

Several research analysts recently commented on OSUR shares. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Finally, BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $18.21.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Earnings History for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.